IL217920A - 5- (3,4-Dichloro-phenyl) -n- (2-Hydroxy-Cyclohexyl) -6- (2,2,2-Trifluoro-Ethoxy) nicotinamide and its salts - Google Patents

5- (3,4-Dichloro-phenyl) -n- (2-Hydroxy-Cyclohexyl) -6- (2,2,2-Trifluoro-Ethoxy) nicotinamide and its salts

Info

Publication number
IL217920A
IL217920A IL217920A IL21792012A IL217920A IL 217920 A IL217920 A IL 217920A IL 217920 A IL217920 A IL 217920A IL 21792012 A IL21792012 A IL 21792012A IL 217920 A IL217920 A IL 217920A
Authority
IL
Israel
Prior art keywords
nicotinamide
trifluoro
dichloro
ethoxy
cyclohexyl
Prior art date
Application number
IL217920A
Other languages
English (en)
Hebrew (he)
Other versions
IL217920A0 (en
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL217920A0 publication Critical patent/IL217920A0/en
Publication of IL217920A publication Critical patent/IL217920A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL217920A 2009-09-11 2012-02-02 5- (3,4-Dichloro-phenyl) -n- (2-Hydroxy-Cyclohexyl) -6- (2,2,2-Trifluoro-Ethoxy) nicotinamide and its salts IL217920A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (en) 2009-09-11 2010-09-08 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents

Publications (2)

Publication Number Publication Date
IL217920A0 IL217920A0 (en) 2012-03-29
IL217920A true IL217920A (en) 2015-11-30

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
IL217920A IL217920A (en) 2009-09-11 2012-02-02 5- (3,4-Dichloro-phenyl) -n- (2-Hydroxy-Cyclohexyl) -6- (2,2,2-Trifluoro-Ethoxy) nicotinamide and its salts

Country Status (34)

Country Link
US (1) US8227491B2 (OSRAM)
EP (1) EP2475645B1 (OSRAM)
JP (1) JP5604520B2 (OSRAM)
KR (1) KR101382871B1 (OSRAM)
CN (1) CN102639506B (OSRAM)
AR (2) AR078352A1 (OSRAM)
AU (1) AU2010294277B2 (OSRAM)
BR (1) BR112012005511B8 (OSRAM)
CA (1) CA2771493C (OSRAM)
CL (1) CL2012000611A1 (OSRAM)
CO (1) CO6491033A2 (OSRAM)
CR (1) CR20120089A (OSRAM)
CY (1) CY1114377T1 (OSRAM)
DK (1) DK2475645T3 (OSRAM)
EC (1) ECSP12011723A (OSRAM)
ES (1) ES2423821T3 (OSRAM)
HR (1) HRP20130869T1 (OSRAM)
IL (1) IL217920A (OSRAM)
IN (1) IN2012DN00763A (OSRAM)
MA (1) MA33563B1 (OSRAM)
MX (1) MX2012002254A (OSRAM)
MY (1) MY161103A (OSRAM)
NZ (1) NZ597514A (OSRAM)
PE (1) PE20120863A1 (OSRAM)
PL (1) PL2475645T3 (OSRAM)
PT (1) PT2475645E (OSRAM)
RS (1) RS52987B (OSRAM)
RU (1) RU2541475C2 (OSRAM)
SG (1) SG179035A1 (OSRAM)
SI (1) SI2475645T1 (OSRAM)
TW (1) TWI412363B (OSRAM)
UA (1) UA107088C2 (OSRAM)
WO (1) WO2011029827A1 (OSRAM)
ZA (1) ZA201201599B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (en) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7
US20200085810A1 (en) * 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
BRPI0609685A2 (pt) 2005-04-06 2010-04-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos
RU2454405C2 (ru) * 2006-10-04 2012-06-27 Ф.Хоффманн-Ля Рош Аг Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина

Also Published As

Publication number Publication date
AR078352A1 (es) 2011-11-02
PL2475645T3 (pl) 2013-12-31
IL217920A0 (en) 2012-03-29
US8227491B2 (en) 2012-07-24
TW201114427A (en) 2011-05-01
BR112012005511B1 (pt) 2021-03-02
PE20120863A1 (es) 2012-07-23
ZA201201599B (en) 2012-11-28
KR20120048040A (ko) 2012-05-14
NZ597514A (en) 2013-10-25
CN102639506A (zh) 2012-08-15
CR20120089A (es) 2012-03-22
AU2010294277B2 (en) 2015-07-09
IN2012DN00763A (OSRAM) 2015-06-26
CA2771493C (en) 2017-08-29
EP2475645A1 (en) 2012-07-18
HRP20130869T1 (hr) 2013-10-25
RU2541475C2 (ru) 2015-02-20
CO6491033A2 (es) 2012-07-31
MA33563B1 (fr) 2012-09-01
AU2010294277A1 (en) 2012-02-09
MX2012002254A (es) 2012-03-16
ES2423821T3 (es) 2013-09-24
RU2012113924A (ru) 2013-10-20
HK1172021A1 (en) 2013-04-12
WO2011029827A1 (en) 2011-03-17
DK2475645T3 (da) 2013-07-22
CA2771493A1 (en) 2011-03-17
AR114032A2 (es) 2020-07-15
MY161103A (en) 2017-04-14
TWI412363B (zh) 2013-10-21
BR112012005511B8 (pt) 2021-05-25
PT2475645E (pt) 2013-08-05
SG179035A1 (en) 2012-04-27
SI2475645T1 (sl) 2013-10-30
CL2012000611A1 (es) 2012-09-07
RS52987B (sr) 2014-02-28
CN102639506B (zh) 2014-09-03
ECSP12011723A (es) 2012-04-30
US20110065759A1 (en) 2011-03-17
CY1114377T1 (el) 2016-08-31
BR112012005511A2 (pt) 2016-04-19
JP5604520B2 (ja) 2014-10-08
EP2475645B1 (en) 2013-07-03
KR101382871B1 (ko) 2014-04-08
UA107088C2 (xx) 2014-11-25
JP2013504534A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
IL204663A0 (en) Nicotinamide derivatives, preparastion thereof and therapeutic use thereof
IL214614A0 (en) Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
EP2360155A4 (en) 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
IL216132A (en) Heterocyclic carboxamide diamine compounds, their uses and their medicinal products and inhibitors
GB2443287B (en) Methods, compositions and formulations for the treatment of thyroid eye disease
SG10201604819TA (en) 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
AP2012006301A0 (en) Synergistic herbicidal composition containing aminopyralid and sulfonylureas.
IL187302A0 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
PT2493306E (pt) Composição herbicida sinergistica coontendo fluroxipir e cihalofop
IL211566A0 (en) 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases
SI2252300T1 (sl) Uporaba 2,4-pirimidindiaminov za zdravljenje ateroskleroze
EP2308493A4 (en) ENHANCING OR THERAPEUTIC AGENT FOR DYSLIPIDEMIA
ZA200806293B (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
IL207389A0 (en) Alpha 7 nicotinic agonists and antipsychotics
EP2139334A4 (en) CONDENSED HETEROCYCLIC 2-CYANOPHENYL COMPOUNDS AND COMPOSITIONS AND THEIR USE
IL210937A (en) New phenyl – amino isonicotinamide compounds and their use
EP2089392A4 (en) 3- (DIHYDRO-1H-PYRAZOLO Ý4,3-D¨PYRIMIDIN-5-YL) -4-PROPOXYBENZENESULFONAMIDE DERIVATIVES AND METHODS OF USE
IL223543A (en) Pharmaceutical preparation containing 1– (4– (4– (4,3-dichloro-2 – fluorophenylamino) –7 – methoxyquinazoline – 6 – Iloxy) piperidine – 1 – il) Prof. 2 – an – 1 – on or a common pharmaceutical salt His and an acidic addition
PL2475645T3 (pl) 5-(3,4-dichlorofenylo)-n-(2-hydroksycykloheksylo)-6-(2,2,2- trifluoroetoksy)nikotynoamid i jego sole jako środki zwiększające poziom cholesterolu hdl
PL2646010T3 (pl) Kombinacja kwas foliowy-ramipryl: kompozycje okulistyczne chroniące komórki, neuroprotekcyjne i retinoprotekcyjne
WO2010115125A3 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
EP2016388A4 (en) PARTICLE MONITORING DEVICE
EP2394649A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL-CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF
ZA200808284B (en) Personal care article
ZA200709777B (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed